GCH1 Gene DYT5A Dopa-Responsive Dystonia Genetic Test in UAE – DHA Licensed

Executive Summary & Core Metrics

The GCH1 Gene DYT5A Genetic Test utilises next-generation sequencing to detect pathogenic variants in the GCH1 gene, providing definitive molecular confirmation for dopa-responsive dystonia (DYT5A). This certified assay delivers 99.9% diagnostic sensitivity through dual-bioinformatics analysis pipelines and meets rigorous ISO 9001:2015 standards. Test results are interpreted alongside clinical evaluation by a DHA-licensed consultant medical geneticist, enabling precise treatment planning.

• Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Next Generation Sequencing (NGS). Every result validated by dual-bioinformatics pipelines.
• Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. Accepts whole blood, extracted DNA, or FTA card.
• Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed consultant medical geneticist or genetic counsellor.
• Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – we verify your policy instantly.

Test Overview & Methodology

This NGS-based test sequences the full GCH1 gene, including exons, intron-exon boundaries, and regulatory regions, to identify single nucleotide variants and copy-number variations causative of DYT5A dystonia. Unlike Sanger sequencing, which is limited to selected exons, our assay provides comprehensive coverage with >100× mean depth, ensuring detection of mosaic variants and structural rearrangements. Results are typically available within 12 to 14 business days.

Feature	Our NGS Test (GCH1 Full Gene)	Closest Alternative (Sanger exons)
Methodology	NGS – full gene sequencing (exons, intron‑exon boundaries, regulatory regions)	Sanger sequencing – selected exons only
Depth / Coverage	>100× mean coverage, identifying CNVs/indels	Single‑base resolution, limited to amplicon
Turnaround Time	3‑4 weeks	4‑6 weeks
Cost (AED)	2800	~3500 (varies)
Sample Types	Whole Blood (EDTA), Extracted DNA, FTA Card (single drop)	Whole Blood only

Physician Insight & Safety Protocols

“As a Consultant Medical Geneticist specialising in movement disorders, I recognise the profound impact that a definitive molecular diagnosis has on guiding therapy for patients with suspected dopa-responsive dystonia. This NGS-based assay provides comprehensive GCH1 gene analysis, identifying variants that may require long-term levodopa management. However, genetic results must always be contextualised within the full clinical picture—a negative finding does not exclude a dystonia syndrome, and any positive result warrants immediate specialist referral to optimise treatment and avoid unnecessary medication adjustments.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

⚠ Medication Warning

Do not discontinue or adjust any prescribed medication (especially levodopa, anticholinergics, or muscle relaxants) without consulting your treating physician. Genetic results may guide therapy, but abrupt changes can provoke severe dystonic crises or withdrawal symptoms.

🚑 Patient Safety – Exclusion Criteria & ER Red Flags

Exclusion: Acute febrile illness, active infection, or recent trauma – reschedule once stable.
Exclusion: Known coagulopathy or severe anaemia (for venipuncture). Alternative: FTA card collection.
ER Red Flag: Sudden onset of severe generalised dystonia, difficulty breathing, swallowing, or speaking → proceed to nearest Emergency Department immediately.
ER Red Flag: New‑onset seizures, confusion, or altered consciousness after sample collection → call 998 for ambulance.

Patient FAQ & Clinical Guidance

1. How accurate is the GCH1 gene test for diagnosing dopa-responsive dystonia?

A: Our NGS‑based test achieves >99.9% diagnostic sensitivity for single nucleotide variants and copy‑number changes within the GCH1 gene, making it the gold standard for identifying DYT5A‑causing mutations.

2. My child is under 18 – can this be performed in the UAE?

A: Yes, with mandatory genetic counselling and a signed consent from a legal guardian, fully compliant with UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.

3. What sample can I provide if a blood draw is difficult?

A: We accept a single drop of blood on an FTA card, extracted DNA, or whole blood – all collected by our cold‑chain mobile phlebotomy team.

UAE Regulatory & Data Privacy Adherence

This diagnostic service operates under the regulatory framework of the Dubai Health Authority (DHA) and complies fully with UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data handling. Genetic test data is encrypted, processed in-country, and never shared without explicit patient consent. The laboratory follows Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields to ensure secure telemedicine and data management. Clinical safety and patient consent procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability.

Clinical & Logistical Metadata

Test Name	GCH1 Gene DYT5A Dopa-Responsive Dystonia Genetic Test – NGS Full Gene Sequencing
Price (AED)	2,800 AED
Turnaround Time	12–14 business days (3–4 weeks)
Sample Type / Matrix	Whole Blood (EDTA), Extracted DNA, FTA Card (single drop)
Methodology Used	Next Generation Sequencing (NGS) – Full gene sequencing, >100× mean coverage
ICD-10-CM Code	G24.1 (Genetic torsion dystonia), G24.8 (Other dystonia), Z13.858 (Encounter for screening for other nervous system disorders)
LOINC Code	95623-1 – GCH1 gene mutations found by sequencing
DHA Facility License & Laboratory Address	License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE